Adiponectin (ADP) is an adipocytokin with many antiatherogenic properties; its decreased level is associated with numerous atherogenic diseases and syndromes (e.g. diabetes mellitus (DM), dyslipidemia, endothelial dysfunction, hypertension, and obesity). Decreased ADP values in blood may be an independent risk factor of atherosclerotic (ATS) complications.
Adiponectin is an adipocytokin with numerous antiatherogenic properties. Its antiatherogenic effect is mediated through its binding ability to collagen and antiinflammatory influence.
The results obtained in the present study indicate that adiponectin is a direct link between obesity and coronary heart disease (CHD) origin; its anti-inflammatory effect was proved as well as its positive effect on metabolism with regard to prevention of atherogenesis 13 . On the basis of several recent papers reporting on direct relation between coronary heart disease, diabetes mellitus (DM) and adiponectin we focused on the following aspects: -Do persons with type 2 DM have lower adiponectin levels than persons with a high risk of atherosclerotic complications without DM? -Do adiponectin levels differ in type 2 DM with wellcontrolled from those in uncontrolled persons with type 2 DM? atherosclerosis (obesity, hypertension, age, family history, dyslipidemia, etc.). Individuals with creatinin over 120 umol/l, persons with clinical signs of system inflammation and persons with type 1 DM were excluded from the study. In all persons under study, the following parameters were determined in peripheral venous blood: adiponectin (ELISA sandwich, Biovendor), resistin (ELISA sandwich, Biovendor), leptin (ELISA sandwich, Biovendor), leptin receptor ObRe (ELISA sandwich, Biovendor), cholesterol (enzyme, BioVendor), HDL-cholesterol (direct assay, BioVendor), triacylglycerols (enzyme, BioVendor), glucose (enzyme, Lachema), HbA1c (HPLC affinitive boronate, Primus), creatinin (Jaffe), urea (enzyme, BioVendor), ALT (IFCC, BioVendor), AST (IFCC, BioVendor), CRP ultrasensitive (LEIA, DPC), blood count (Coulter), homocystein (LEIA, DPC), IGF-1 (LEIA, DPC), thrombocyte aggregation after induction by cationic propylgallate (CPG).
The whole group was divided according to the presence of type 2 DM into two subgroups; the group of persons with diabetes mellitus was divided according to compensation level into the short-term (long-term) compensated and non-compensated individuals. The criterion of satisfactory long-term compensation in persons with DM was the concentration of fructosamine <270 µmol/l.
The individuals with ASA resistance were persons with values (aggregometry) slope after CPG induction >53 %/min and/or values of spontaneous aggregability >5 %.
The persons with inflammation were persons with CPR concentration >15 mg/l. All data were processed by SPSS software for Windows and Medcalc. Associated quantities are expressed as mean ± standard deviation, unless otherwise stated. Adiponectin concentrations in the groups were compared by the method of distribution analysis (ANOVA, Kruskal Wallis tests), by means of non-parametric Student t tests and ROC analysis. Adiponectin concentrations and other quantities were mutually correlated using Spearmann correlation coefficient. Category data were compared by χ 2 test, p < 0.05 was considered to be statistically significant. Women had higher adiponectin values than men. Distribution analysis showed that persons with hypertension, with diabetes mellitus, individuals with atherogenic lipotype and persons with inflammation signs had lower adiponectin values than subjects without these diseases and syndromes. Patients with satisfactory long-term compensation had higher ADP values that longterm "decompensated" individuals. The level of short-term compensation did not play a role in adiponectin values.
RESULTS
Patients treated with ASA (100 mg/day) had significantly higher adiponectin values than individuals not treated with ASA; no differences were found between those subgroups (in contrast to persons with/without diabetes mellitus, men/women in other characteristics (Table 1) .
Adiponectin values were not affected by complementary insulin therapy, oral antidiabetic drugs or their combination. No differences in adiponectin concentration were found in persons with osteoporosis, ASA resistance, smokers, individuals treated with statins, fibrates or their combination, HRT or raloxifen (Table 2) .
DISCUSSION
In 1995, a report was published on adipocyte-produced protein, which is present in the serum (30 kDa). This protein was named adiponectin, or Acrp30 (adipocyte complement-related protein of 30 kDa), GBP28 (gelating binding protein 28 kDa) or AdipoQ. Adiponectin is structurally similar to collagen and C1q (contains collagen-similar domains and C1q-like globular domain) and displays a high binding ability to collagen 8, 38 . This adipocytokin differs from most adipose tissueproduced proteins by decreased production in obese and insulin-resistant persons (e.g. in contrast to leptin or resistin). The most important effects of adiponectin are stimulated phosphorylation of Ac-Co-A carboxylase, stimulated oxidation of free fatty acids, stimulated metabolism of glucose and lactate, reduction of gluconeogenetic enzymes, improved effectiveness of insulin, inhibition of local growth factors, production of some cytokines, etc. In summary, adiponectin exhibits important "antidiabetic" and "antiatherogenic" effects (the term of adipovascular axis is used) 15 . Expression of adiponectin and its concentration in the blood is regulated by many substances (insulin, corticoids, catecholamines, adhesive molecules, cytokines and adipocytokines, estrogens, androgens, prolactin, IGF-1, PPAR-gamma, etc. . Adiponectin concentration is under a strong genetic control. It was proved that relatives of persons with type 2 DM have decreased expression (by about 45 %) of adiponectin in adipose tissue, but normal adiponectin serum concentration. In these persons an impaired adiponectin regulation may be present 19 . It seems probable that higher adiponectin concentration may predict an increased insulin sensitivity. Such correlation is independent of fat mass and probably affects directly lipoprotein concentration and insulin-mediated production of non-esterified fatty acids (NEFA) 12, 15 . This hypothesis is supported by the fact that glitasons (e.g. rosiglitason) protects the organism against the lipidinduced insulin resistance (particularly in the liver). This effect may be mediated by a chronic elevation of adiponectin during the therapy with glitasons (a two-week daily therapy results in adiponectin elevation by about 130-200 %) 12 . The study of the Pima Indians (population with a high type 2 DM prevalence and incidence) verified that a high adiponectin concentration is associated with a low risk of type 2 DM 2, 29 . It was found that the atherogenic lipotype (hypertriacy lglycerolemia, enhanced ApoB, reduced HDL-cholesterol, slight elevation of LDL-cholesterol or enhanced ApoE or NEFA) is associated with reduced adiponectin concentration even in persons without diabetes mellitus. Reduction of adiponectin may probably account for the origin of metabolic syndrome 31 . On the contrary, a positive correlation between HDL-cholesterol (ApoAI) and adiponectin is considered as another evidence of possible use of adiponectin as an antiatherogenic marker 2 . The above-mentioned findings suggested the existence of the so-called adipovascular axis. Certain adipocytokin seem to play a role even in the origin of atherosclerosis 15 .
Adiponectin synthesis was found to be reduced in subjects with CHD and endothelial dysfunction. Reduced adiponectin concentration is associated with CHD incidence (independently of the presence of DM, relative amount fat, BMI, dyslipoproteinemia, hypertension, smoking). The study reporting this finding indicated that men with hypoadiponectinemia have a significalty higher risk of CHD, independently of other risk factors 3, 30 . Adipocytes are known to produce several biologically active substances responsible for the origin of hypertension. Adiponectin appears to affect the origin of hypertension (persons with essential hypertension were found to have lower adiponectin concentrations). A negative correlation was proved between adiponectin and mean systolic and diastolic blood pressure. The above findings indicate that standardization of metabolic variations in persons with limit values of blood pressure would be desirable; adiponectin assessment may be very useful when considering a type of intervention 5, 9, 32 . Adiponectin is accumulated mainly in the affected veins where reduces the endothelial inflammatory response, proliferation of smooth muscle cells and transformation of macrophages. Experimental studies proved that hypoadiponectinemia is associated with proliferation of smooth muscle cells of veins and excess production of growth factors (EGF, HB-EGF, BFGF) 12 . In this context therapeutical approaches are speculated, namely adiponectin elevation through pharmacological or non-pharmacological intervention and thus prevent restenoses of coronary arteries 14, 28 . Our study confirmed recent findings that persons with diabetes mellitus have significantly lower adiponectin concetrations than persons without DM (even after adjustment to BMI) and that adiponectin concentration correlates negatively with insulin resistance markers. We also confirmed that persons with hypertension and atherogenic lipotype have reduced adiponectin concentrations in serum.
Highly interesting is the fact that adiponectin in persons with type 2 DM correlated negatively with HbA1c (independently of fructosamine concentration). The obtained results suggest that the subgroups DM/non-DM have higher differences in adiponectin concentration than in BMI. This may be due to the fact that the presence of DM is associated more with reduced production of adiponectin than a more obesity without DM. Adiponectin levels may be related to DM control and severity of dyslipidemia. Thus, adiponectin may be a new marker of metabolic control of individuals with high risk of cardiovascular complications of atherosclerosis.
This hypothesis is supported also by our next finding that persons with inflammation signs had low adiponectin concentrations. This corresponds to the findings of relations between adipocytokines and the presence of inflammation, i.e. correlations between the present inflammation and manifestation of atherosclerotic complications.
It should be pointed out that individuals treated with 100 mg of ASA/day had lower adiponectin concentrations in serum than the ASA non-treated persons. It is supposed that ASA may influence the concentration of some inflammatory agents.
CONCLUSION
Persons with type 2 DM have lower adiponectin concetrations in serum than patients with a high risk of atherosclerotic complications without DM. Individuals with satisfactory DM control have significantly higher adiponectin concentrations (irrespective of other metabolic markers of DM control). Adiponectin may be a novel marker of metabolic control of persons with a high risk of cardiovascular complications of atherosclerosis. 
Adiponectin concentrations as a criterion of metabolic control in persons with type 2 diabetes mellitus?

